Three Weill Department of Medicine Faculty Accepted to the American Society of Clinical Investigation (ASCI)


Dr. Daniel Fitzgerald

The Weill Department of Medicine has had three of its faculty elected as members of the American Society of Clinical Investigation (ASCI) – Dr. Daniel W. Fitzgerald, Dr. Steven M. Lipkin, and Dr. Kyu Y. Rhee. Membership to ASCI is a coveted honor and reflects landmark contributions in the area of clinical investigation.

Founded in 1908, the American Society of Clinical Investigation is an honor society of some 3,000 physician-scientists who serve in the upper ranks of academic medicine and industry. Those who become members of ASCI are premier leaders in translating findings from the laboratory to the advancement of clinical practice. Dr. Fitzgerald, Associate Professor of Medicine, and Dr. Rhee, Associate Professor of Medicine, are faculty members of the Division of Infectious Diseases. Dr. Lipkin, Associate Professor of Medicine and Genetic Medicine, is a faculty member in the Division of Gastroenterology and Hepatology.

Dr. Kyu Rhee

"Drs. Fitzgerald, Lipkin, and Rhee exemplify outstanding investigative research at its best, and our department congratulates them on this prestigious honor," said Dr. Augustine M.K. Choi, Sanford I. Weill Chair, Weill Department of Medicine.

For nearly two decades, Dr. Fitzgerald has pioneered research in the field of global health working with GHESKIO in Haiti. Published in top tier journals such as the New England Journal of Medicine and Lancet, he is known for his role in furthering critical advances for the treatment of HIV/AIDS and tuberculosis. He is the Co-Director of the Center for Global Health in the Division of Infectious Diseases and was recently named the Co-Director of the department's new three-year Global Health Research Fellowship. Dr. Fitzgerald has educated numerous trainees on the techniques of field-based research within Weill Cornell programs around the globe.

Steven Lipkin

Dr. Steven Lipkin

Dr. Rhee is an infectious diseases physician interested in modernizing our understanding of major infectious pathogens and the ability to develop new diagnostic tests and therapies. Toward this end, he has developed new mass spectrometry-based tools to expand our understanding of the pathogenicity of Mycobacterium tuberculosis, the leading bacterial cause of deaths worldwide, on a global biochemical level as well as to introduce a new approach to developing TB drugs.

Dr. Lipkin's research focuses on hereditary cancer syndromes and mouse models for cancer prevention research. He completed a specialty fellowship in Clinical Genetics at the National Human Genome Research Institute and performed his post-doctoral work in the laboratory of Francis Collins, who is currently the Director of the National Institutes of Health. Dr. Lipkin is board certified in Clinical Genetics and is a fellow of the American Board of Medical Genetics.